Cargando…

Complement Activation Profile in Myasthenia Gravis Patients: Perspectives for Tailoring Anti-Complement Therapy

The complement system plays a key role in myasthenia gravis (MG). Anti-complement drugs are emerging as effective therapies to treat anti-acetylcholine receptor (AChR) antibody-positive MG patients, though their usage is still limited by the high costs. Here, we searched for plasma complement protei...

Descripción completa

Detalles Bibliográficos
Autores principales:	Iacomino, Nicola, Vanoli, Fiammetta, Frangiamore, Rita, Ballardini, Marta, Scandiffio, Letizia, Bortone, Federica, Andreetta, Francesca, Baggi, Fulvio, Bernasconi, Pia, Antozzi, Carlo, Cavalcante, Paola, Mantegazza, Renato
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9220000/ https://www.ncbi.nlm.nih.gov/pubmed/35740382 http://dx.doi.org/10.3390/biomedicines10061360

Ejemplares similares

Complement Inhibition for the Treatment of Myasthenia Gravis
por: Mantegazza, Renato, et al.
Publicado: (2020)

miR-146a in Myasthenia Gravis Thymus Bridges Innate Immunity With Autoimmunity and Is Linked to Therapeutic Effects of Corticosteroids
por: Bortone, Federica, et al.
Publicado: (2020)

Muscle and Muscle-like Autoantigen Expression in Myasthenia Gravis Thymus: Possible Molecular Hint for Autosensitization
por: Iacomino, Nicola, et al.
Publicado: (2023)

Iatrogenic Kaposi’s sarcoma in myasthenia gravis: learnings from two case reports
por: Frangiamore, Rita, et al.
Publicado: (2021)

Development and validation of the Myasthenia Gravis TeleScore (MGTS)
por: Pasqualin, F., et al.
Publicado: (2022)

Animal models of myasthenia gravis: utility and limitations
por: Mantegazza, Renato, et al.
Publicado: (2016)

From Traditional to Targeted Immunotherapy in Myasthenia Gravis: Prospects for Research
por: Mantegazza, Renato, et al.
Publicado: (2020)

When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies
por: Mantegazza, Renato, et al.
Publicado: (2018)

Impact of Ravulizumab on Patient Outcomes and Quality of Life in Generalized Myasthenia Gravis
por: Antozzi, Carlo, et al.
Publicado: (2023)

Current and emerging therapies for the treatment of myasthenia gravis
por: Mantegazza, Renato, et al.
Publicado: (2011)

Amifampridine phosphate in the treatment of muscle-specific kinase myasthenia gravis: a phase IIb, randomized, double-blind, placebo-controlled, double crossover study
por: Bonanno, Silvia, et al.
Publicado: (2018)

Epstein-Barr virus in tumor-infiltrating B cells of myasthenia gravis thymoma: an innocent bystander or an autoimmunity mediator?
por: Cavalcante, Paola, et al.
Publicado: (2017)

Role of complement in myasthenia gravis
por: San, Pyae Phyo, et al.
Publicado: (2023)

Inflammation and Epstein-Barr Virus Infection Are Common Features of Myasthenia Gravis Thymus: Possible Roles in Pathogenesis
por: Cavalcante, Paola, et al.
Publicado: (2011)

Summary of Research: Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis
por: Vu, Tuan, et al.
Publicado: (2023)

Complement Inhibitor Therapy for Myasthenia Gravis
por: Albazli, Khaled, et al.
Publicado: (2020)

Therapeutic Effect of Bifidobacterium Administration on Experimental Autoimmune Myasthenia Gravis in Lewis Rats
por: Rinaldi, Elena, et al.
Publicado: (2019)

Role of complement in the pathogenesis of experimental autoimmune myasthenia gravis
Publicado: (1978)

Complement deposition at the neuromuscular junction in seronegative myasthenia gravis
por: Hoffmann, Sarah, et al.
Publicado: (2020)

Administration of bifidobacterium and lactobacillus strains modulates experimental myasthenia gravis and experimental encephalomyelitis in Lewis rats
por: Consonni, Alessandra, et al.
Publicado: (2018)

Myasthenia Gravis
por: Aarli, Johan A., et al.
Publicado: (2011)

VAV1 and BAFF, via NFκB pathway, are genetic risk factors for myasthenia gravis
por: Avidan, Nili, et al.
Publicado: (2014)

Immunological response after SARS-CoV-2 infection and mRNA vaccines in patients with myasthenia gravis treated with Rituximab
por: Damato, Valentina, et al.
Publicado: (2023)

Immunoblot analysis of antiAChR antibodies in myasthenia gravis
por: Mantegazza, R., et al.
Publicado: (1988)

Myasthenia gravis complement activity is independent of autoantibody titer and disease severity
por: Fichtner, Miriam L., et al.
Publicado: (2022)

Anti-Spike IgG in multiple sclerosis patients after BNT162b2 vaccine: An exploratory case-control study in Italy
por: Giossi, Riccardo, et al.
Publicado: (2022)

Heterogeneity of Acetylcholine Receptor Autoantibody–Mediated Complement Activity in Patients With Myasthenia Gravis
por: Obaid, Abeer H., et al.
Publicado: (2022)

Next-Generation Sequencing Identifies Extended HLA Class I and II Haplotypes Associated With Early-Onset and Late-Onset Myasthenia Gravis in Italian, Norwegian, and Swedish Populations
por: Creary, Lisa E., et al.
Publicado: (2021)

Consistent improvement with eculizumab across muscle groups in myasthenia gravis
por: Mantegazza, Renato, et al.
Publicado: (2020)

Eculizumab improves fatigue in refractory generalized myasthenia gravis
por: Andersen, Henning, et al.
Publicado: (2019)

Ravulizumab pharmacokinetics and pharmacodynamics in patients with generalized myasthenia gravis
por: Vu, Tuan, et al.
Publicado: (2023)

Correction to: Eculizumab improves fatigue in refractory generalized myasthenia gravis
por: Andersen, Henning, et al.
Publicado: (2019)

Complement regulatory protein Crry deficiency contributes to the antigen specific recall response in experimental autoimmune myasthenia gravis
por: Soltys, Jindrich, et al.
Publicado: (2012)

Receptor clustering and pathogenic complement activation in myasthenia gravis depend on synergy between antibodies with multiple subunit specificities
por: Rose, Natalie, et al.
Publicado: (2022)

Immunological and Structural Characterization of Titin Main Immunogenic Region; I110 Domain Is the Target of Titin Antibodies in Myasthenia Gravis
por: Stergiou, Christos, et al.
Publicado: (2023)

Suppression of CHRN endocytosis by carbonic anhydrase CAR3 in the pathogenesis of myasthenia gravis
por: Du, Ailian, et al.
Publicado: (2017)

Myasthenia gravis
por: Juel, Vern C, et al.
Publicado: (2007)

Myasthenia Gravis
Publicado: (1905)

Myasthenia Gravis
por: Wilson, Andrew
Publicado: (1952)

Myasthenia Gravis
por: Bramwell, Edwin
Publicado: (1901)

Cannot write session to /tmp/vufind_sessions/sess_lo7kbel1ua19pchf3m8fsmh1lh